Download PDF
Thromb Haemost 2003; 89(05): 915-925
DOI: 10.1055/s-0037-1613479
Cellular Proteolysis and Oncology
Schattauer GmbH

Inhibition of PMN-elastase activity by semisynthetic glucan sulfates

Markus Becker
1   Institute of Pharmacy, University of Regensburg, Regensburg, Germany
,
Gerhard Franz
1   Institute of Pharmacy, University of Regensburg, Regensburg, Germany
,
Susanna Alban
2   Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Germany
› Author Affiliations
Further Information

Publication History

Received 04 November 2002

Accepted after revision 02 February 2003

Publication Date:
09 December 2017 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Proteolysis of connective tissue by enzymes such as PMN-elastase (PMNE) is a crucial step during inflammation and metastasis. Semisynthetic sulfated carbohydrates (SC) were shown to exhibit potent antiinflammatory and antimetastatic activity in vivo. The aim of the present study was to examine whether interferences with PMN-elastase may contribute to these effects. Therefore, the interactions of these compounds with PMNE were evaluated in various test systems. Besides semisynthetic α-1,4/1,6- and β-1,3-glucan sulfates, UFH, a LMWH and pentosan polysulfate (PPS) were included in the study. The inhibitory activity of SC improves not only with increasing molecular weight (MW 10 – 250 kDa: 37 – 54% inhibition at 0.25 µg/ml) and degree of sulfation (DS 0.25 - 2.0: 16 - 50% inhibition at 0.25 µg/ml), but depends also on their genuine polysaccharide structure (IC50 β-1,3-glucan sulfate 0.18 / α-1,4/1,6-glucan sulfate 0.25 / UFH 0.5 µg/ml). Using physiological substrate assays (collagen, elastin), β-1,3- and α-1,4/1,6-glucan sulfates are more active than UFH (inhibition at 1.5 µg/ml: 41 / 32 / 12%). According to enzyme-inhibitor binding studies, SC exhibit structure dependent affinity to the enzyme (Kd for PMNE: β-1,3 < α-1,4/1,6 < UFH). Finally, SC were shown to inhibit cancer cell-mediated elastinolysis.

Keywords

PMN-elastase - glucan sulfates - heparin - inflammation - metastasis
 

  • References

  • 1 Janoff A, Scherer J.. Mediators of inflammation in leukocyte lysosomes. IX. Elastinolytic activity in granules of human polymorphnucelear leukocytes. J Exp Med 1968; 128: 1137-40.
    CrossrefPubMedGoogle Scholar
  • 2 Travis J.. Structure, function, and control of neutrophil proteinases. Am J Med 1988; 84 6A 37-42.
    CrossrefPubMedGoogle Scholar
  • 3 Havemann K, Gramse M.. Physiology and pathophysiology of neutral proteinases of human granulocytes. Adv Exp Med Biol 1984; 167: 1-20.
    PubMedGoogle Scholar
  • 4 Starkey PM, Barrett AJ, Burleigh MC.. The degradation of articular collagen by neutrophil proteinases. Biochim Biophys Acta 1977; 483 (02) 386-97.
    CrossrefPubMedGoogle Scholar
  • 5 Dallegri F, Ottonello L.. Tissue injury in neutrophilic inflammation. Inflamm Res 1997; 46 (10) 382-91.
    CrossrefPubMedGoogle Scholar
  • 6 Bieth JG.. Elastase: catalytic and biological properties. In: Biology of Extra-Cellular Matrix, vol. 1: Regulation of Matrix Accumulation. Mecham R.P... ed New York: Academic Press; 1986: 217-320.
    Google Scholar
  • 7 Campbell EJ, Campbell MA.. Pericellular proteolysis by neutrophils in the presence of proteinase inhibitors: effects of substrate opsonization. J Cell Biol 1988; 106 (03) 667-76.
    CrossrefPubMedGoogle Scholar
  • 8 Janoff A, Carp H, Laurent P, Raju L.. The role of oxidative processes in emphysema. Am Rev Respir Dis 1983; 127 (02) 31-8.
    PubMedGoogle Scholar
  • 9 Carp H, Miller F, Hoidal JR, Janoff A.. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci USA 1982; 79 (06) 2041-5.
    CrossrefPubMedGoogle Scholar
  • 10 Lee CT, Fein AM, Lippmann M, Holtzman H, Kimbel P, Weinbaum G.. Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome. N Engl J Med 1981; 304 (04) 192-6.
    CrossrefPubMedGoogle Scholar
  • 11 Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y.. Increased neutrophil elastase, persistent intravascular coagulation, and decreased fibrinolytic activity in patients with posttraumatic acute respiratory distress syndrome. J Trauma 1997; 42 (06) 1068-72.
    CrossrefPubMedGoogle Scholar
  • 12 Tanaka H, Sugimoto H, Yoshioka T, Sugimoto T.. Role of granulocyte elastase in tissue injury in patients with septic shock complicated by multiple-organ failure. Ann Surg 1991; 213 (01) 81-5.
    CrossrefPubMedGoogle Scholar
  • 13 Duswald KH, Jochum M, Schramm W, Fritz H.. Released granulocytic elastase: an indicator of pathobiochemical alterations in septicemia after abdominal surgery. Surgery 1985; 98 (05) 892-9.
    PubMedGoogle Scholar
  • 14 Hansen G, Schuster A, Zubrod C, Wahn V.. Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum. Respiration 1995; 62 (03) 117-24.
    CrossrefPubMedGoogle Scholar
  • 15 Hansen G, Hoffjan S, Mosler K, Schuster A.. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients. Lung 2001; 179 (03) 185-94.
    CrossrefPubMedGoogle Scholar
  • 16 Menninger H, Putzier R, Mohr W, Wessinghage D, Tillmann K.. Granulocyte elastase at the site of cartilage erosion by rheumatoid synovial tissue. Z Rheumatol 1980; 39 5-6 145-56.
    PubMedGoogle Scholar
  • 17 Momohara S, Kashiwazaki S, Inoue K, Saito S, Nakagawa T.. Elastase from polymorphonu-clear leukocyte in articular cartilage and synovial fluids of patients with rheumatoid arthritis. Clin Rheumatol 1997; 16 (02) 133-40.
    CrossrefPubMedGoogle Scholar
  • 18 Orem A, Deger O, Cimsit G, Bahadir S.. Plasma polymorphonuclear leukocyte elastase levels and its relation to disease activity in psoriasis. Clin Chim Acta 1997; 264 (01) 49-56.
    CrossrefPubMedGoogle Scholar
  • 19 Rogalski C, Meyer-Hoffert U, Proksch E, Wiedow O.. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo. J Invest Dermatol 2002; 118 (01) 49-54.
    CrossrefPubMedGoogle Scholar
  • 20 Yamashita J, Tashiro K, Yoneda S, Kawahara K, Shirakusa T.. Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer. Chest 1996; 109 (05) 1328-34.
    CrossrefPubMedGoogle Scholar
  • 21 Yamashita J, Ogawa M, Abe M, Hayashi N, Kurusu Y, Kawahara K, Shirakusa T.. Tumor neutrophil elastase is closely associated with the direct extension of non-small cell lung cancer into the aorta. Chest 1997; 111 (04) 885-90.
    CrossrefPubMedGoogle Scholar
  • 22 Yamashita JI, Ogawa M, Ikei S, Omachi H, Yamashita SI, Saishoji T, Nomura K, Sato H.. Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonu-clear leucocyte elastase in the progression of human breast cancer. Br J Cancer 1994; 69 (01) 72-6.
    CrossrefPubMedGoogle Scholar
  • 23 Grant AJ, Russell PJ.. Raghavan. Elastase activities of human bladder cancer cell lines derived from high grade invasive tumours. Biochem Biophys Res Commun 1989; 162 (01) 308-15.
    CrossrefPubMedGoogle Scholar
  • 24 De Noncourt P, Robledo O, Alain T, Kossakowska AE, Urbanski SJ, Potworowski EF, St-Pierre Y.. Leukocyte elastase in murine and human non-Hodgkin lymphomas. J Leukoc Biol 2001; (04) 585-91.
    PubMedGoogle Scholar
  • 25 Yamashita J, Ogawa M, Shirakusa T.. Free-form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer. J Leukoc Biol 1995; 57 (03) 375-8.
    CrossrefPubMedGoogle Scholar
  • 26 Baici A, Salgam P, Fehr K, Boni A.. Inhibition of human elastase from polymorphonuclear leucocytes by a glycosaminoglycan polysul-fate (Arteparon). Biochem Pharmacol 1980; 29 (12) 1723-7.
    CrossrefPubMedGoogle Scholar
  • 27 Baici A, Bradamante P.. Interaction between human leukocyte elastase and chondroitin sul-fate. Chem Biol Interact 1984; 51 (01) 1-11.
    CrossrefPubMedGoogle Scholar
  • 28 Lafuma C, Frisdal E, Harf A, Robert L, Hornebeck W.. Prevention of leucocyte elastase-induced emphysema in mice by heparin fragments. Eur Respir J 1991; 4 (08) 1004-9.
    PubMedGoogle Scholar
  • 29 Tian Y, Gebitekin C, Martin P, Satur CM, Mearns A, Walker DR.. Influence of heparin thromboprophylaxis on plasma leucocyte elastase levels following lobectomy for lung carcinoma. Blood Coagul Fibrinolysis 1995; 6 (06) 527-30.
    CrossrefPubMedGoogle Scholar
  • 30 Linhardt RJ, Merchant ZM, Rice KG, Kim YS, Fitzgerald GL, Grant AC, Langer R.. Evidence of random structural features in the heparin polymer. Biochemistry 1985; 24 (26) 7805-10.
    CrossrefPubMedGoogle Scholar
  • 31 Rosenberg RD.. Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc 1977; 36 (01) 10-8.
    PubMedGoogle Scholar
  • 32 Yvin J-C, Alban S, Franz G.. Anti-inflammatory and healing medicine based on laminarin sulphate. PCT Int. Appl. Patent No. WO 2002036132 (10.05.2002).
    PubMedGoogle Scholar
  • 33 Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA, Vlodavsky I.. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphor-othioate oligodeoxynucleotides. Int J Cancer 1999; 83 (03) 424-31.
    CrossrefPubMedGoogle Scholar
  • 34 Alban S.. Carbohydrates with anticoagulant and antithrombotic properties. VII. In. Witczak ZJ, Nieforth KA.. Ed., Carbohydrates in Drug Design New York: Marcel Dekker; 1997: pp. 209-276.
    Google Scholar
  • 35 Alban S, Franz G.. Partial synthetic glucan sulfates as potential new antithrombotics. Biomacromolecules 2001; 2 (02) 354-61.
    CrossrefPubMedGoogle Scholar
  • 36 Doherty JB, Ashe BM, Argenbright LW, Barker PL, Bonney RJ, Chandler GO, Dahlgren ME, Dorn Jr CP, Finke PE, Firestone RA.. et al. Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase. Nature 1986; 322 6075 192-4.
    CrossrefPubMedGoogle Scholar
  • 37 Ying QL, Rinehart AR, Simon SR, Cheronis JC.. Inhibition of human leucocyte elastase by ursolic acid. Evidence for a binding site for pentacyclic triterpenes. Biochem J 1991; 277 (Pt 2) 521-6.
    CrossrefPubMedGoogle Scholar
  • 38 Alban S, Schauerte A, Franz G.. Anticoagulant sulphated polysaccharides: I. Synthesis and structure-activity relationships of new pullulan sulfates. Carbohydr Polym 2001; 47: 267-76.
    PubMedGoogle Scholar
  • 39 Alban S, Franz G.. Gas-liquid chromatography-mass spectrometry analysis of anticoagulant active curdlan sulfates. Semin Thromb Hemost 1994; 20 (02) 152-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Kramps JA, van Twisk C, van der Linden AC.. L-Pyroglutamyl-L-prolyl-L-valine-p-nitroanilide, a highly specific substrate for granulocyte elastase. Scand J Clin Lab Invest 1983; 43 (05) 427-32.
    CrossrefPubMedGoogle Scholar
  • 41 Nethery A, Lyons JG, O’Grady RL.. A spec-trophotometric collagenase assay. Anal Biochem 1986; 159 (02) 390-5.
    CrossrefPubMedGoogle Scholar
  • 42 Wiedow O, Luademann J, Utecht B.. Elafin is a potent inhibitor of proteinase 3. Biochem Biophys Res Commun 1991; 174 (01) 6-10.
    CrossrefPubMedGoogle Scholar
  • 43 Alban S, Gastpar R.. Development of SPCELISA: a new assay principle for the study of sulphated polysaccharide-protein interactions. J Biomol Screen 2001; 6 (06) 393-400.
    PubMedGoogle Scholar
  • 44 Kao RT, Stern R.. Elastases in human breast carcinoma cell lines. Cancer Res 1986; 46 (03) 1355-8.
    PubMedGoogle Scholar
  • 45 Walsh RL, Dillon TJ, Scicchitano R, McLennan G.. Heparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin Sci (Lond) 1991; 81 (03) 341-6.
    CrossrefPubMedGoogle Scholar
  • 46 Bode W, Wei AZ, Huber R, Meyer E, Travis J, Neumann S.. X-ray crystal structure of the complex of human leukocyte elastase (PMN elastase) and the third domain of the turkey ovomucoid inhibitor. EMBO J 1986; 5 (10) 2453-8.
    PubMedGoogle Scholar
  • 47 Bode W, Meyer Jr E, Powers JC.. Human leukocyte and porcine pancreatic elastase: Xray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. Biochemistry 1989; 28 (05) 1951-63.
    CrossrefPubMedGoogle Scholar
  • 48 Kostoulas G, Horler D, Naggi A, Casu B, Baici A.. Electrostatic interactions between human leukocyte elastase and sulphated glycosaminoglycans: physiological implications. Biol Chem 1997; 378 (12) 1481-9.
    PubMedGoogle Scholar
  • 49 Baici A.. Graphical and statistical analysis of hyperbolic tight-binding inhibition. Biochem J 1987; 244 (03) 793-6.
    CrossrefPubMedGoogle Scholar
  • 50 Bartolucci C, Cellai L, Iannelli MA, Lamba D, Liverani L, Mascellani G, Perola E.. Inhibition of human leukocyte elastase by chemically and naturally oversulphated galactosaminoglycans. Carbohydr Res 1995; 276 (02) 401-8.
    CrossrefPubMedGoogle Scholar
  • 51 Volpi N.. Inhibition of human leukocyte elastase activity by heparins: influence of charge density. Biochim Biophys Acta 1996; 1290 (03) 299-307.
    CrossrefPubMedGoogle Scholar
  • 52 Alban S, Stibich H, Franz G.. Partialsynthetic β-1,3-glucan sulfates as specific complement inhibitors or compounds with anticomplement as well as anticoagulant activities for producing biocompatible surfaces. Thromb Haemost 1999 Suppl: PS 1866.
    PubMedGoogle Scholar
  • 53 Alban S, Becker M.. Modification of the action profile of heparins and sulfated carbohydrates with elastase inhibiting and anticoagulant activities. Ann Hematol 2002; 81 Suppl I: A1 3.
    PubMedGoogle Scholar
  • 54 Wessel HP, Bartsch S.. Conformational flexibility in highly sulfated beta-D-glucopyranoside derivatives. Carbohydr Res 1995; 274: 1-9.
    CrossrefPubMedGoogle Scholar
  • 55 Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J.. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res 1994; 74 (03) 193-205.
    CrossrefPubMedGoogle Scholar
  • 56 Alban S, Becker M, Franz G.. Interactions of sulfated polysaccharides with the t-PA-mediated plasminogen activation. Ann Hematol 2001; 80 Suppl I A3/3.
    PubMedGoogle Scholar
  • 57 Yomtova VM, Stambolieva NA, Blagoev BM.. Kinetic study of the effect of heparin on the amidase activity of trypsin, plasmin and urokinase. Thromb Haemost 1983; 28 49 (03) 199-203.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Cadene M, Boudier C, de Marcillac GD, Bieth JG.. Influence of low molecular mass heparin on the kinetics of neutrophil elastase inhibition by mucus proteinase inhibitor. J Biol Chem 1995; 270 (22) 13204-9.
    CrossrefPubMedGoogle Scholar
  • 59 Ying QL, Kemme M, Saunders D, Simon SR.. Glycosaminoglycans regulate elastase inhibition by oxidized secretory leukoprotease inhibitor. Am J Physiol 1997; 272 (3 Pt 1) L533-41.
    PubMedGoogle Scholar
  • 60 Campbell EJ, Senior RM, McDonald JA, Cox DL.. Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J Clin Invest 1982; 70 (04) 845-52.
    CrossrefPubMedGoogle Scholar
  • 61 Morrison HM, Welgus HG, Owen CA, Stockley RA, Campbell EJ.. Interaction between leukocyte elastase and elastin: quantitative and catalytic analyses. Biochim Biophys Acta 1999; 1430 (02) 179-90.
    CrossrefPubMedGoogle Scholar
  • 62 Campbell EJ, Silverman EK, Campbell MA.. Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity. J Immunol 1989; 143 (09) 2961-8.
    PubMedGoogle Scholar
  • 63 Zacharski LR, Ornstein DL.. Heparin and cancer. Thromb Haemost 1998; 80 (01) 10-23.
    Article in Thieme ConnectPubMedGoogle Scholar